FYB.DE Stock — Price, Charts & Analysis

Formycon AG (FYB.DE) has no trailing P/E shown and a forward P/E of 17.38x. This places FYB.DE in a moderate earnings multiple territory based on the valuation data currently available on Worldtickers.

FYB.DE trades with 17.38x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether FYB.DE looks overvalued or undervalued.

FYB.DE's P/E of 17.38x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

FYB.DE's trailing EPS is -€1.42 and forward EPS is €1.11.

EPS, or earnings per share, shows how much profit Formycon AG generated for each share. FYB.DE's trailing EPS is -€1.42, and investors usually prefer EPS that is positive and growing over time.

Formycon AG has a market cap of €341.09M, making FYB.DE a small-cap stock based on the current market value shown on Worldtickers.

FYB.DE's latest stock price on Worldtickers is €19.30. The latest move is €0.64 or 3.43%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

FYB.DE's quote includes a latest price of €19.30. The market open is €18.80. Previous close is €18.66. The intraday range is €18.66 to €19.44.

FYB.DE is up in the latest quote, with a move of €0.64 or 3.43%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

FYB.DE generated €61.24M in trailing revenue. Revenue growth is 242.50%, which helps show whether demand is expanding or slowing.

FYB.DE's revenue growth is 242.50%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

No, FYB.DE does not show positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is -€25.13M.

Gross margin is 22.81%. Margins show how efficiently Formycon AG turns revenue into profit.

Formycon AG carries €8.52M and holds €51.78M in cash.

FYB.DE holds €51.78M on its balance sheet.

FYB.DE's book value per share is €21.76.

Institutions hold 31.26% of FYB.DE shares. Insiders hold 30.00% of shares. Ownership mix helps investors understand how much of Formycon AG is held by professional investors and company insiders.

FYB.DE has 17.67M shares outstanding. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for FYB.DE, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for FYB.DE is €1.11. Revenue growth is 242.50%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

FYB.DE's trailing EPS is -€1.42. Forward EPS is €1.11. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

FYB.DE is in the Healthcare sector. Its earnings multiple is 17.38x. Its latest displayed growth metric is 242.50%. Compare these figures with sector peers before deciding whether Formycon AG is stronger or weaker than average.

FYB.DE trades at €19.30. The stock trades at 17.38x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Formycon AG's fundamentals.

FYB.DE risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.72, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

FYB.DE should be compared with companies in Biotechnology. Its earnings multiple is 17.38x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Formycon AG (FYB.DE) operates in Healthcare, specifically Biotechnology. Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn

FYB.DE trades on XETRA. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

FYB.DE stock is priced in EUR on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Formycon AG's official website listed on Worldtickers is www.formycon.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Formycon AG employs about 196 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Formycon AG is headquartered in Planegg, Germany. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

FYB.DE is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

FYB.DE has traded between €15.80 and €26.95 over the past 52 weeks. At €19.30, it is 28.39% below the high and 22.15% above the low. The 52-week range helps gauge long-term price momentum.

FYB.DE is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. Its 50-day moving average is €18.96 and its 200-day moving average is €20.81.

FYB.DE's RSI is 57.32. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

FYB.DE's latest RSI reading is 57.32, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for FYB.DE is near €18.00. Key resistance is near €19.54. Breaks above resistance or below support can change the short-term technical setup.

FYB.DE's nearest reported support level is €18.00. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

FYB.DE's nearest reported resistance level is €19.54. A breakout above resistance can improve momentum, especially when volume confirms the move.

FYB.DE trades about 5.78K shares daily on average. The latest displayed volume is 5.24K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

FYB.DE's MACD is 0.05, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

FYB.DE is between its 50-day and 200-day moving averages, which suggests a mixed trend setup. RSI is 57.32 (neutral). MACD is bullish. Nearest support is around €18.00. Resistance is around €19.54. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is €18.81 (2.59% from price). MA50 is €18.96 (1.79% from price). MA200 is €20.81 (-7.25% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. FYB.DE's MA20 is €18.81. MA50 is €18.96. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

FYB.DE's pivot is near €18.49. Support is near €18.00. Resistance is near €19.54. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for FYB.DE is near €18.57. The next upper resistance zone is near €20.23. These levels help define risk and possible follow-through zones after a breakout or breakdown.

FYB.DE's Bollinger range is roughly €18.29 to €19.34. Band width is near 5.55%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

FYB.DE's ATR-based typical daily range is about 3.16%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 5.24K shares. Average volume is about 5.78K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

FYB.DE's all-time high shown on Worldtickers is €94.10. Its all-time low is €1.74. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

FYB.DE has a beta of 0.72, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.